NCT04468984
Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis No drug interventions treatment 3 active_not_recruiting NCT04472598
Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis treatment 3 active_not_recruiting NCT03222609
A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis treatment 2 active_not_recruiting NCT06414681
Combination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy With the Approved JAK Inhibitors or in Which Therapy With the Approved JAK Inhibitors is Not Appropriate, Contraindicated or Declined No drug interventions treatment 0 not_yet_recruiting NCT05115344
Study of Flonoltinib Maleate Tablets in the Treatment of Proliferative Bone Marrow Tumors No drug interventions other 1 unknown_status NCT05153343
Safety of Flunotinib Maleate Tablets for the Treatment of Patients With Myeloproliferative No drug interventions other 1 / 2 recruiting NCT01211691
Study of KB004 in Subjects With Hematologic Malignancies (Myelodysplastic Syndrome, MDS, Myelofibrosis, MF) No drug interventions treatment 1 / 2 suspended NCT01816256
Screening for Asymptomatic Portal Vein Thrombosis and Portal Hypertension in Patients With Philadelphia Negative Myeloproliferative Neoplasms No drug interventions screening Not Available completed NCT06541249
MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) Trial No drug interventions treatment 2 not_yet_recruiting NCT01224496
Traditional Chinese Medicine in the Supportive Management of Anaemic and Cytopenic (Leukopenia, Thrombocytopenia) Haematological Disorders No drug interventions supportive_care 1 / 2 completed NCT04454658
Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis No drug interventions treatment 1 active_not_recruiting NCT04480086
Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitoclax Tablet in Adult Participants With Myelofibrosis No drug interventions treatment 1 terminated NCT04728490
Haplo-identical Transplantation in Patients With Myelofibrosis - A Phase 2 Prospective Multicentric Prospective Study No drug interventions treatment 2 unknown_status NCT00522990
Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias No drug interventions treatment 1 / 2 terminated NCT05535764
Allogeneic Hematopoietic Cell Transplantation With Pegylated Interferon Alfa-2a for Primary and Secondary Myelofibrosis No drug interventions treatment 1 recruiting NCT05371964
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis No drug interventions treatment 1 recruiting NCT03912064
A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT No drug interventions treatment 1 active_not_recruiting NCT04097821
Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients No drug interventions treatment 1 / 2 active_not_recruiting NCT01291784
Anti-TGF-beta Therapy in Patients With Myelofibrosis No drug interventions treatment 1 terminated NCT02916979
Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG No drug interventions treatment 1 completed NCT01340651
Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients treatment 2 completed NCT04551053
To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304) treatment 3 terminated NCT03373877
Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis treatment 1 terminated NCT01795677
JAK2 Inhibitors RUXOLITINIB in Patients With Myelofibrosis No drug interventions treatment 2 completed NCT02934477
Prospective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis No drug interventions Not Available Not Available recruiting NCT02807077
PK of Pacritinib in Patients With Mild, Moderate, Severe Renal Impairment and ESRD Compared to Healthy Subjects other 1 completed NCT00667277
Phase II Study of Bevacizumab (Avastin®) in Myelofibrosis treatment 2 terminated NCT00807677
A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies treatment 1 completed NCT00715247
Polycythemia Vera, Myelofibrosis and Essential Thrombocythemia: Identification of PV, MF & ET Genes No drug interventions Not Available Not Available completed NCT04279847
Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms treatment 1 recruiting NCT05805605
Allo HSCT Using RIC and PTCy for Hematological Diseases treatment 2 recruiting NCT04153305
European Registry for Myeloproliferative Neoplasms (MPNs) - Update of ERNEST Study No drug interventions Not Available Not Available completed NCT05031897
Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant treatment 2 recruiting NCT00572897
Study of Fludarabine Based Conditioning for Allogeneic Stem Cell Transplantation for Myelofibrosis treatment 2 completed NCT05582083
Managed Access Program for Momelotinib in Myelofibrosis Not Available Not Available no_longer_available NCT01300611
TXA127 in Enhancement of Engraftment in Adult Double Cord Blood Transplantation supportive_care 1 terminated NCT04218071
Actuate 1901: 9-ING-41 in Myelofibrosis treatment 2 completed NCT02181478
Intra-Osseous Co-Transplant of UCB and hMSC treatment 0 completed NCT03745378
Secondary Cancers in Myeloproliferative Neoplasms (MPN-K Study) No drug interventions Not Available Not Available completed NCT05025488
Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm treatment 1 recruiting NCT00719888
Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease treatment 2 active_not_recruiting NCT04817007
A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis) treatment 1 / 2 active_not_recruiting NCT00852709
Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias treatment 1 terminated NCT00136409
A Study of Gleevec in Patients With Idiopathic Myelofibrosis or Chronic Myelomonocytic Leukemia (CMML) treatment 2 completed NCT04217356
Study of Stem Cell Transplant vs. Non-Transplant Therapies in High-Risk Myelofibrosis Not Available Not Available recruiting NCT04866056
Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF. treatment 1 / 2 terminated NCT02440685
A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors treatment 1 / 2 terminated NCT04988815
Ropeginterferon Alfa 2b for Early Myelofibrosis treatment 2 recruiting NCT00606437
Total Body Irradiation With Fludarabine Followed by Combined Umbilical Cord Blood (UCB) Transplants No drug interventions treatment 1 completed NCT04640532
KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intolerant MF treatment 1 / 2 recruiting NCT03560752
CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant supportive_care 1 active_not_recruiting NCT00975975
Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer treatment 2 completed NCT01814475
Study to Compare Busulfan-fludarabine With Thiotepa-fludarabine Regimen in Allogeneic Transplantation for Myelofibrosis treatment 2 completed NCT05410470
Efficacy and Safety of Ruxolitinib in Patients With Myelofibrosis Not Available Not Available completed NCT00309842
Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases treatment 2 completed NCT01758042
Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders No drug interventions treatment Not Available recruiting NCT00509899
Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis treatment 1 / 2 completed NCT03878199
Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms treatment 1 / 2 recruiting NCT02370706
Study of the Safety of PIM447 in Combination With Ruxolitinib (INC424) and LEE011 in Patients With Myelofibrosis health_services_research 1 completed NCT03964506
Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant No drug interventions treatment 0 recruiting NCT00666549
Research Tissue Bank No drug interventions Not Available Not Available completed NCT00719836
A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid Malignancies treatment 1 / 2 completed NCT02564536
Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS) treatment 1 withdrawn NCT03907436
The NUTRIENT Trial (NUTRitional Intervention Among myEloproliferative Neoplasms): Feasibility Phase No drug interventions treatment Not Available completed NCT06397313
RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis treatment 2 not_yet_recruiting NCT02530619
Alisertib in Treating Patients With Myelofibrosis or Relapsed or Refractory Acute Megakaryoblastic Leukemia treatment Not Available unknown_status NCT04888741
Methods of T Cell Depletion Trial (MoTD) prevention 2 recruiting NCT06245941
A Clinical Trial of TQ05105 Tablets Combined With TQB3909 Tablets in the Treatment of Myelofibrosis (MF) No drug interventions treatment 1 / 2 recruiting NCT02530034
Hu8F4 in Treating Patients With Advanced Hematologic Malignancies No drug interventions treatment 1 active_not_recruiting NCT02396134
Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant No drug interventions supportive_care 2 active_not_recruiting NCT03645824
Myelofibrosis Treated With Pacritinib Before aSCT. (HOVON134MF) treatment 2 active_not_recruiting NCT02784496
Long-Term Side Effects of Ruxolitinib in Treating Patients With Myelofibrosis treatment 2 completed NCT04709458
Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis No drug interventions treatment 1 not_yet_recruiting NCT02167958
Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source treatment 1 completed NCT04851535
Study of Jaktinib In Patients With Myelofibrosis Who Were Relapsed or Refractory of Ruxolitinib Treatment. treatment 2 completed NCT06063486
Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms No drug interventions treatment 2 recruiting NCT02426086
Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor treatment 2 completed NCT00997386
Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure States treatment 2 completed NCT03333486
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer treatment 2 active_not_recruiting NCT03952039
An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib treatment 3 active_not_recruiting NCT04629430
Effects of Prebiotics on Gut Microbiome in Patients Undergoing HSCT No drug interventions treatment Not Available completed NCT02493530
TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea treatment 1 completed NCT03723148
Individual Patient Compassionate Use of Fedratinib Not Available Not Available available NCT06398457
Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies treatment 0 not_yet_recruiting NCT03069326
A Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With Myelofibrosis treatment 2 active_not_recruiting NCT01692366
Phase 2 Study in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly treatment 2 completed NCT04551066
To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313) treatment 3 active_not_recruiting NCT05123365
An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms treatment 1 / 2 recruiting NCT03452774
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry No drug interventions Not Available Not Available recruiting NCT00522574
A Safety Study of XL019 in Adults With Myelofibrosis treatment 1 terminated NCT05762874
Ruxolitinib in Patients With Myelofibrosis Not Available Not Available not_yet_recruiting NCT03314974
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders No drug interventions treatment 2 recruiting NCT01520220
Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms treatment 1 completed NCT00475020
Allogeneic Stem Cell Transplantation for Myelofibrosis and Myelodysplastic Syndrome treatment 2 completed NCT00354120
Thymoglobuline Versus Alemtuzumab in Patients Undergoing Allogeneic Transplant No drug interventions treatment 2 / 3 completed NCT06351631
A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017) treatment 3 recruiting NCT02556931
Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies treatment 2 completed NCT03592576
Expanded Access to Navitoclax Not Available Not Available no_longer_available NCT02593760
A Study to Evaluate the Efficacy and Safety of Vismodegib in Combination With Ruxolitinib for the Treatment of Intermediate- or High-Risk Myelofibrosis (MF) treatment 1 completed NCT04485260
An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib treatment 1 / 2 recruiting NCT00569660
Ph II Study of Azacitidine in Myelofibrosis treatment 2 completed NCT05455294
Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms treatment 1 active_not_recruiting NCT00352794
Lenalidomide for Patients With Myelofibrosis (MF) treatment 2 completed NCT00235391
Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload treatment 3 completed NCT00631462
A Dose-escalation Study of the Safety and Tolerability of Orally Administered TG101348 in Patients With Myelofibrosis treatment 1 completed NCT00148980
Creation of Bone Marrow Microenvironment for Treatment of Myelodysplastic Syndrome (MDS) in Conjunction With Allogeneic Stem Cell Transplantation No drug interventions Not Available 2 withdrawn NCT00393380
Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor prevention 2 terminated NCT05665192
A Study to Assess Real-World Patient-Reported Outcomes With Fedratinib for Myelofibrosis Post-Ruxolitinib No drug interventions Not Available Not Available recruiting NCT03438344
Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications in Patients With Blood Cancer Undergoing Donor Stem Cell Transplant No drug interventions supportive_care 2 withdrawn NCT05279001
A Safety and Tolerability Study of Jaktinib No drug interventions treatment 1 recruiting NCT04771572
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. No drug interventions treatment 1 recruiting NCT00087672
A Phase II Study of CC-5013 in Myelofibrosis No drug interventions treatment 2 completed NCT05444972
A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource Utilization in Adult Participants With Myelofibrosis Through Chart Review No drug interventions Not Available Not Available completed NCT02805868
Siltuximab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis No drug interventions treatment 0 withdrawn NCT03566446
CALR Exon 9 Mutant Peptide Vaccine to Patients With CALR-mutant Myeloproliferative Neoplasms No drug interventions treatment 1 completed NCT03289910
Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia No drug interventions treatment 2 active_not_recruiting NCT02660281
URMC Related Haplo-identical Donor BMT No drug interventions treatment 1 completed NCT01149681
Clinical Trial of Aplidin® in Patients With Primary Myelofibrosis No drug interventions treatment 2 completed NCT03802695
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies No drug interventions treatment 1 recruiting NCT01493414
INC424 for Patients With Primary Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis. No drug interventions treatment 3 completed NCT02435550
iCare for Cancer Patients No drug interventions diagnostic Not Available terminated NCT00745550
A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis No drug interventions treatment 1 / 2 completed NCT04629508
To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213) No drug interventions treatment 2 completed NCT01712308
Sotatercept in Treating Patients With Myeloproliferative Neoplasm-Associated Myelofibrosis or Anemia No drug interventions treatment 2 completed NCT00594308
In-Vivo Activated T-Cell Depletion to Prevent GVHD No drug interventions treatment Not Available terminated NCT00668421
CEP-701 (Lestaurtinib) in Myelofibrosis No drug interventions treatment 1 / 2 unknown_status NCT04282421
Survival in Myelofibrosis Patients After Allogeneic Hematopoietic Stem Cell Transplantation in Five Centers in France No drug interventions Not Available Not Available completed NCT01290302
Bioequivalence Trial of Luitpold Azacitidine Versus Vidaza® in Patients With Myelodysplastic Syndrome, Myelofibrosis, Chronic Myeloid Leukemia or Chronic Lymphocytic Leukemia No drug interventions treatment 1 completed NCT02730884
Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia No drug interventions treatment 2 terminated NCT04543279
Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia No drug interventions treatment 2 terminated NCT02506933
Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant No drug interventions supportive_care 2 active_not_recruiting NCT00723333
Bone Marrow Transplant Chart Review for RIC No drug interventions Not Available Not Available completed NCT02065154
Post Transplant Cyclophosphamide (Cytoxan) for GvHD Prophylaxis No drug interventions prevention 2 completed NCT02268253
Tagraxofusp (SL-401) in Patients With CMML or MF No drug interventions treatment 2 completed NCT05972577
Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study No drug interventions supportive_care Not Available active_not_recruiting NCT04060277
Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation No drug interventions supportive_care 2 active_not_recruiting NCT01499147
Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies No drug interventions treatment Not Available completed NCT00599547
Allogeneic Stem Cell Transplantation (SCT) After Dose-reduced Conditioning for Myelofibrosis Patients No drug interventions treatment 2 completed NCT01369498
Efficacy and Safety of Simtuzumab in Adults With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis No drug interventions treatment 2 completed NCT05320198
Study of DISC-0974 in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia No drug interventions treatment 1 / 2 recruiting NCT03602898
Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation No drug interventions treatment 2 withdrawn NCT04176198
A Study of Oral TP-3654 in Patients With Myelofibrosis No drug interventions treatment 1 / 2 recruiting NCT05875805
A Telehealth Advance Care Planning Intervention No drug interventions supportive_care Not Available recruiting NCT06164561
18F-FAPI PET/MRI Imaging in Myelofibrosis: a Prospective Observational Study. No drug interventions Not Available Not Available recruiting NCT00287261
A Trial of Zoledronic Acid in Patients With Myelofibrosis With Myeloid Metaplasia (MMM) No drug interventions treatment 2 completed NCT04617028
Jaktinib Versus Hydroxycarbamide in Subjects With Intermediate-2 or High-risk Myelofibrosis No drug interventions treatment 3 completed NCT05710211
Clonal Architecture of ASXL1-mutated Myelofibrosis No drug interventions other Not Available not_yet_recruiting NCT03959371
Ruxolitinib in Myelofibrosis Patients in Lombardy, Italy No drug interventions Not Available Not Available unknown_status NCT01758588
Pegylated Interferon Alpha-2b in Early Primary Myelofibrosis No drug interventions treatment 2 terminated NCT02581007
Reduced Intensity Conditioning Transplant Using Haploidentical Donors No drug interventions treatment 2 completed NCT05280509
Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib No drug interventions treatment 1 / 2 recruiting NCT04576156
A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment No drug interventions treatment 3 recruiting NCT00494585
CEP-701 for PH-negative Myelofibrosis No drug interventions treatment 2 completed NCT00463385
A Phase II Study of Pomalidomide in Myelofibrosis With Myeloid Metaplasia No drug interventions treatment 2 completed NCT03136185
Bomedemstat (IMG-7289/MK-3543) in Participants With Myelofibrosis (IMG-7289-CTP-102/MK-3543-002) No drug interventions treatment 1 / 2 completed NCT06001385
HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis No drug interventions treatment 2 recruiting NCT03886415
Jaktinib Hydrochloride Tablets in Intermediate-risk and High-risk Myelofibrosis. No drug interventions treatment 2 completed NCT06024915
A Study to Evaluate Drug-Drug Interaction of TQ05105 Tablets No drug interventions treatment 1 not_yet_recruiting NCT06378437
A Study of GLB-001 in Patients With Myeloid Malignancies No drug interventions treatment 1 recruiting NCT02728700
Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HSCT No drug interventions prevention 1 terminated NCT06388759
TQ05105 Tablet for Myelofibrosis Treatment in Ruxolitinib-Resistant or Intolerant Patients No drug interventions treatment 1 active_not_recruiting NCT01317875
Study of the JAK Inhibitor Ruxolitinib Administered Orally to Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF) No drug interventions treatment 1 completed NCT04562870
A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis No drug interventions treatment 2 active_not_recruiting NCT04679870
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral GB2064 in Participants With Myelofibrosis No drug interventions treatment 2 active_not_recruiting NCT01956799
Identification of Mechanism in the Erythroid Response in Patients With Myelodysplasia Undergoing Chelation Therapy No drug interventions Not Available Not Available completed NCT05980806
A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia No drug interventions treatment 2 recruiting NCT05982106
To Evaluate the Effect of Food on the Pharmacokinetics of TQ05105 Tablets in Healthy Adult Subjects No drug interventions other 1 completed NCT06516406
Ruxolitinib in Primary Myelofibrosis and Secondary to Essential Thrombocythemia or Polycythemia Vera No drug interventions Not Available Not Available recruiting NCT01962636
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases No drug interventions treatment Not Available recruiting NCT06533813
Clinical Epidemiology in Contemporary Patients With Myelofibrosis. No drug interventions Not Available Not Available not_yet_recruiting NCT04655118
Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis No drug interventions treatment 2 recruiting NCT03755518
A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib No drug interventions treatment 3 completed NCT05233618
Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MF and CMML (HSCT 002) No drug interventions treatment 1 recruiting NCT00724334
A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis No drug interventions treatment 1 / 2 completed NCT02765724
Determine Pacritinib Pharmacokinetics in Impaired Hepatic Patients and Healthy Subjects No drug interventions other 1 completed NCT02742324
Trial Ruxolitinib and Peg-interferon Alpha-2a Combination in Patients With Primary Myelofibrosis RUXOPeg No drug interventions treatment 1 / 2 completed NCT02910258
Interferon-pegyle α2a Efficiency and Tolerance in Myelofibrosis No drug interventions Not Available Not Available completed NCT02158858
A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis No drug interventions treatment 1 / 2 active_not_recruiting NCT00360035
Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in the Treatment of Myelofibrosis With Myeloid Metaplasia No drug interventions treatment 2 completed NCT06479135
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib No drug interventions treatment 3 recruiting NCT02436135
Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Adults Receiving Ruxolitinib as Therapy for Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis With Progressive or Relapsed Disease No drug interventions treatment 1 terminated NCT04640025
A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib No drug interventions treatment 2 active_not_recruiting NCT04666025
SARS-CoV-2 Donor-Recipient Immunity Transfer No drug interventions Not Available Not Available completed NCT02663648
Cell Cycle Regulatory Gene Study in Patients With Myeloproliferative Disorders No drug interventions Not Available Not Available withdrawn NCT01730248
A Study to Find the Maximum Tolerated Dose of the Experimental Combination of the Drugs INC424 and BKM120 in Patients With Primary or Secondary Myelofibrosis No drug interventions treatment 1 terminated NCT06150157
A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms No drug interventions treatment 1 recruiting NCT04283526
Study of Select Combinations in Adults With Myelofibrosis No drug interventions treatment 1 withdrawn NCT03427866
Ruxolitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis. No drug interventions treatment 2 active_not_recruiting NCT00572065
Pilot Trial of Arsenic + Cytarabine in Patients With Myelofibrosis No drug interventions treatment 0 completed NCT02469974
Ruxolitinib in Combination With Autotransplant No drug interventions treatment Not Available withdrawn NCT00081874
RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma No drug interventions treatment 1 / 2 completed NCT01417520
Clinical and Pathophysiological Investigations Into Erdheim Chester Disease No drug interventions Not Available Not Available completed NCT02129582
Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies No drug interventions treatment 1 completed NCT02877082
Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients No drug interventions prevention 2 terminated NCT06122831
A Clinical Trial of TQ05105 Tablets Combined With TQB3617 Capsules in the Treatment of Myelofibrosis (MF) No drug interventions treatment 1 / 2 recruiting NCT04354727
A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy No drug interventions treatment 1 / 2 withdrawn NCT05447260
A New Prognostic Stratification-based Safety and Efficacy Study of Ruxolitinib in Myelofibrosis No drug interventions treatment 4 unknown_status NCT05037760
Study to Evaluate KER-050 as a Monotherapy or in Combination With Ruxolitinib in Myelofibrosis No drug interventions treatment 2 recruiting NCT03480360
Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression No drug interventions treatment 3 active_not_recruiting NCT05423691
Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs No drug interventions treatment 1 recruiting NCT06059391
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant No drug interventions treatment 2 recruiting NCT01398462
Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients No drug interventions treatment 1 completed NCT00069680
Genetic Analysis of Gray Platelet Syndrome No drug interventions Not Available Not Available completed NCT04676529
Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis No drug interventions treatment 1 / 2 active_not_recruiting NCT04464889
HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation No drug interventions treatment 1 withdrawn NCT04562389
Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis No drug interventions treatment 3 recruiting NCT04328844
A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers No drug interventions treatment 1 active_not_recruiting NCT00934544
Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial No drug interventions treatment 3 completed NCT00665067
Correlative Biomarker Study in Patients With Myeloproliferative Disorders No drug interventions Not Available Not Available completed NCT01693601
Panobinostat and Ruxolitinib In MyElofibrosis (PRIME Trial) No drug interventions treatment 1 / 2 completed NCT00255346
Dasatinib as Therapy for Myeloproliferative Disorders (MPDs) No drug interventions treatment 2 completed NCT01973881
Quantitative MRI for Myelofibrosis No drug interventions Not Available Not Available recruiting NCT06345495
High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly No drug interventions treatment 2 not_yet_recruiting NCT04603495
Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2) No drug interventions treatment 3 active_not_recruiting NCT04717414
An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions No drug interventions treatment 3 active_not_recruiting NCT01760655
Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies No drug interventions treatment 2 completed NCT05569538
Bomedemstat (IMG-7289) Plus Ruxolitinib for Myelofibrosis No drug interventions treatment 2 recruiting NCT06132243
Comparative Study on Pharmacokinetics of Two Formulations of Jaktinib in Healthy Adults Under Fasting Conditions No drug interventions treatment 1 completed NCT04816578
To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313) treatment 3 recruiting NCT04816565
To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304) treatment 3 not_yet_recruiting NCT04821791
To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy. (LIMBER-213) treatment 2 recruiting NCT00088231
PTK 787 and Gleevec in Patients With AML, AMM, and CML-BP treatment 1 / 2 completed NCT00506402
A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies No drug interventions treatment 1 completed NCT03326310
Selumetinib and Azacitidine in High Risk Chronic Blood Cancers No drug interventions treatment 1 recruiting NCT03386214
Pevonedistat in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis No drug interventions treatment 1 terminated NCT03718143
AZD1775 in Advanced Acute Myeloid Leukemia, Myelodysplastic Syndrome and Myelofibrosis No drug interventions treatment 2 terminated NCT01929265
A Phase II Study for Patients With Indolent Non-follicular Non-Hodgkin's Lymphoma treatment 2 completed